Monopar Publishes Positive Phase 2 Data for ALXN1840 in Wilson Disease
summarizeSummary
Monopar Therapeutics announced the peer-reviewed publication of positive Phase 2 data for ALXN1840 in Wilson disease, confirming its ability to improve copper balance and supporting its upcoming NDA submission.
check_boxKey Events
-
Phase 2 Study Published
Results from the Phase 2 ALXN1840-WD-204 study, demonstrating ALXN1840's ability to improve copper balance in Wilson disease patients, were published in Hepatology Communications.
-
Significant Copper Balance Improvement
The study showed a statistically significant reduction in daily copper balance and increased fecal copper excretion, even in patients with long-term prior treatment.
-
Reinforces ALXN1840's Potential
This peer-reviewed publication provides further scientific validation for ALXN1840, Monopar's lead candidate, ahead of its targeted mid-2026 NDA submission.
auto_awesomeAnalysis
Monopar Therapeutics announced the peer-reviewed publication of positive Phase 2 clinical trial results for its lead candidate, ALXN1840, in Wilson disease. The study demonstrated significant improvements in copper balance and mobilization, reinforcing the drug's efficacy and safety profile. This publication provides further scientific validation as the company targets a mid-2026 NDA submission for ALXN1840.
At the time of this filing, MNPR was trading at $55.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $369.8M. The 52-week trading range was $28.40 to $105.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.